UK office for QUMAS's European ambitions:
This article was originally published in Clinica
Executive Summary
QUMAS, a developer, marketer and supporter of integrated compliance management products, has opened a sales office in Hemel Hempstead, UK. Under the leadership of Kevin Fitzgerald, the company's vice-president of European sales, the new office will serve as a base for its European development initiatives for the medical device, biotechnology and pharmaceutical industries. Based in Florham Park, New Jersey and Cork, Ireland, QUMAS's products provide solutions for FDA and ISO-related best practices and the automation of controlled documentation and submissions. The products are based on open systems for use in within existing technology infrastructures, whilst the range of services includes validation, training and technical support.
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.